Impact of gut microbiota-mediated bile acid metabolism on the solubilization capacity of bile salt micelles and drug solubility

Molecular Pharmaceutics

Volumn 14, Issue 4, 2017, Pages 1251-1263

  Enright, Elaine F ^a,b   Joyce, Susan A ^a,b   Gahan, Cormac G M ^a,b   Griffin, Brendan T ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Bile acid metabolism; Bile micelle; Biorelevant media; Microbiota; Pharmacokinetics; Poorly water soluble drug; Solubility; Solubilization capacity

Indexed keywords

7ALPHA DEHYDROXYLASE; BILE ACID; BILE SALT; BILE SALT HYDROLASE; CELECOXIB; DANAZOL; DRUG; FELODIPINE; FENOFIBRATE; HYDROCORTISONE; HYDROLASE; KETOCONAZOLE; NIFEDIPINE; OXYGENASE; PHENYTOIN; PROGESTERONE; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; MICELLE; STEROID; WATER;

ARTICLE; BILE ACID METABOLISM; DRUG ABSORPTION; DRUG CONJUGATION; DRUG HYDROXYLATION; DRUG SOLUBILITY; ENZYME ACTIVITY; INTESTINE FLORA; LIPOPHILICITY; MICELLE; MOLECULAR WEIGHT; ORAL ABSORPTION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLUBILIZATION; SURFACE TENSION; BILE; BIOAVAILABILITY; CHEMISTRY; HUMAN; PHYSIOLOGY; SOLUBILITY;

BILE; BILE ACIDS AND SALTS; BIOLOGICAL AVAILABILITY; GASTROINTESTINAL MICROBIOME; HUMANS; MICELLES; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; STEROIDS; TAUROCHOLIC ACID; TAURODEOXYCHOLIC ACID; WATER;

EID: 85019034837     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b01155     Document Type: Article

References (52)

1. Mimee, M.; Citorik, R. J.; Lu, T. K. Microbiome therapeutics - Advances and challenges. Adv. Drug Delivery Rev. 2016, 105 (Part A), 44-54.
2. Enright, E. F.; Gahan, C. G.; Joyce, S. A.; Griffin, B. T. The Impact of the Gut Microbiota on Drug Metabolism and Clinical Outcome. Yale J. Biol. Med. 2016, 89 (3), 375-382.
3. Matuskova, Z.; Anzenbacherova, E.; Vecera, R.; Tlaskalova-Hogenova, H.; Kolar, M.; Anzenbacher, P. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PLoS One 2014, 9 (2), e87150.
4. Niehues, M.; Hensel, A. In-vitro interaction of L-dopa with bacterial adhesins of Helicobacter pylori: an explanation for clinicial differences in bioavailability? J. Pharm. Pharmacol. 2009, 61 (10), 1303-7.
5. Joyce, S. A.; MacSharry, J.; Casey, P. G.; Kinsella, M.; Murphy, E. F.; Shanahan, F.; Hill, C.; Gahan, C. G. M. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (20), 7421-7426.
6. Lipinski, C. Poor aqueous solubility-an industry wide problem in drug discovery. Am. Pharm. Rev. 2002, 5 (3), 82-5.
7. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12 (3), 413-20.
8. Butler, J. M.; Dressman, J. B. The developability classification system: application of biopharmaceutics concepts to formulation development. J. Pharm. Sci. 2010, 99 (12), 4940-54.
9. Fagerberg, J. H.; Tsinman, O.; Sun, N.; Tsinman, K.; Avdeef, A.; Bergstrom, C. A. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol. Pharmaceutics 2010, 7 (5), 1419-30.
10. Lentz, K. A. Current Methods for Predicting Human Food Effect. AAPS J. 2008, 10 (2), 282-288.
11. Begley, M.; Gahan, C. G.; Hill, C. The interaction between bacteria and bile. FEMS Microbiol. Rev. 2005, 29 (4), 625-51.
12. Matsuoka, K.; Suzuki, M.; Honda, C.; Endo, K.; Moroi, Y. Micellization of conjugated chenodeoxy- and ursodeoxycholates and solubilization of cholesterol into their micelles: comparison with other four conjugated bile salts species. Chem. Phys. Lipids 2006, 139 (1), 1-10.
13. Wiedmann, T. S.; Kamel, L. Examination of the Solubilization of Drugs by Bile Salt Micelles. J. Pharm. Sci. 2002, 91 (8), 1743-1764.
14. Persson, E. M.; Gustafsson, A.-S.; Carlsson, A. S.; Nilsson, R. G.; Knutson, L.; Forsell, P.; Hanisch, G.; Lennernäs, H.; Abrahamsson, B. The Effects of Food on the Dissolution of Poorly Soluble Drugs in Human and in Model Small Intestinal Fluids. Pharm. Res. 2005, 22 (12), 2141-2151.
15. Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of Various Dissolution Media for Predicting In Vivo Performance of Class I and II Drugs. Pharm. Res. 1998, 15 (5), 698-705.
16. Jantratid, E.; Janssen, N.; Reppas, C.; Dressman, J. B. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 2008, 25 (7), 1663-76.
17. Hashimoto, S.; Igimi, H.; Uchida, K.; Satoh, T.; Benno, Y.; Takeuchi, N. Effects of beta-lactam antibiotics on intestinal microflora and bile acid metabolism in rats. Lipids 1996, 31 (6), 601-9.
18. Allegretti, J. R.; Kearney, S.; Li, N.; Bogart, E.; Bullock, K.; Gerber, G. K.; Bry, L.; Clish, C. B.; Alm, E.; Korzenik, J. R. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment. Pharmacol. Ther. 2016, 43 (11), 1142-1153.
19. Duboc, H.; Rajca, S.; Rainteau, D.; Benarous, D.; Maubert, M. A.; Quervain, E.; Thomas, G.; Barbu, V.; Humbert, L.; Despras, G.; Bridonneau, C.; Dumetz, F.; Grill, J. P.; Masliah, J.; Beaugerie, L.; Cosnes, J.; Chazouilleres, O.; Poupon, R.; Wolf, C.; Mallet, J. M.; Langella, P.; Trugnan, G.; Sokol, H.; Seksik, P. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 2013, 62 (4), 531-9.
20. Joyce, S. A.; Gahan, C. G. Bile Acid Modifications at the Microbe-Host Interface: Potential for Nutraceutical and Pharmaceutical Interventions in Host Health. Annu. Rev. Food Sci. Technol. 2016, 7, 313-33.
21. Shono, Y.; Jantratid, E.; Janssen, N.; Kesisoglou, F.; Mao, Y.; Vertzoni, M.; Reppas, C.; Dressman, J. B. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur. J. Pharm. Biopharm. 2009, 73 (1), 107-114.
22. Vogt, M.; Kunath, K.; Dressman, J. B. Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur. J. Pharm. Biopharm. 2008, 68 (2), 330-337.
23. Sarma, P. V. G. K. Validaton, quantitative and qualitative analysis of felodipine drug using HPLC. J. Pharm. Res. 2012, 5 (4), 1838-1840.
24. O'Shea, J. P.; Faisal, W.; Ruane-O'Hora, T.; Devine, K. J.; Kostewicz, E. S.; O'Driscoll, C. M.; Griffin, B. T. Lipidic dispersion to reduce food dependent oral bioavailability of fenofibrate: In vitro, in vivo and in silico assessments. Eur. J. Pharm. Biopharm. 2015, 96, 207-216.
25. Zughaid, H.; Forbes, B.; Martin, G. P.; Patel, N. Bile salt composition is secondary to bile salt concentration in determining hydrocortisone and progesterone solubility in intestinal mimetic fluids. Int. J. Pharm. 2012, 422 (1-2), 295-301.
26. Soderlind, E.; Karlsson, E.; Carlsson, A.; Kong, R.; Lenz, A.; Lindborg, S.; Sheng, J. J. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol. Pharmaceutics 2010, 7 (5), 1498-507.
27. Wagner, C.; Thelen, K.; Willmann, S.; Selen, A.; Dressman, J. B. Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation. J. Pharm. Sci. 2013, 102 (9), 3205-19.
28. Teo, S. Y.; Rathbone, M. J.; Coombes, A. G. A.; Lee, S. Y.; Gan, S. N. Development and Validation of a Stability-indicating Isocratic Reverse Phase-Liquid Chromatography Assay for Determination of Phenytoin in Bulk and Pharmaceutical Formulations. Int. J. Pharm. Pharm. Sci. 2015, 7 (8), 6.
29. Schwebel, H. J.; van Hoogevest, P.; Leigh, M. L. S.; Kuentz, M. The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs. Pharm. Dev. Technol. 2011, 16 (3), 278-286.
30. Oh, D. M.; Curl, R. L.; Amidon, G. L. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm. Res. 1993, 10 (2), 264-70.
31. Fagerberg, J. H.; Al-Tikriti, Y.; Ragnarsson, G.; Bergstrom, C. A. Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid. Mol. Pharmaceutics 2012, 9 (7), 1942-52.
32. Ilevbare, G. A.; Liu, H.; Edgar, K. J.; Taylor, L. S. Maintaining Supersaturation in Aqueous Drug Solutions: Impact of Different Polymers on Induction Times. Cryst. Growth Des. 2013, 13 (2), 740-751.
33. Kerč, J.; Srčič, S.; Knez, Ž.; Senčar-Božič, P. Micronization of drugs using supercritical carbon dioxide. Int. J. Pharm. 1999, 182 (1), 33-39.
34. Chu, K. A.; Yalkowsky, S. H. An interesting relationship between drug absorption and melting point. Int. J. Pharm. 2009, 373 (1-2), 24-40.
35. Macheras, P.; Karalis, V.; Valsami, G. Keeping a Critical Eye on the Science and the Regulation of Oral Drug Absorption: A Review. J. Pharm. Sci. 2013, 102 (9), 3018-3036.
36. Bakatselou, V.; Oppenheim, R. C.; Dressman, J. B. Solubilization and wetting effects of bile salts on the dissolution of steroids. Pharm. Res. 1991, 8 (12), 1461-9.
37. Kleberg, K.; Jacobsen, J.; Mullertz, A. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J. Pharm. Pharmacol. 2010, 62 (11), 1656-68.
38. Birru, W. A.; Warren, D. B.; Ibrahim, A.; Williams, H. D.; Benameur, H.; Porter, C. J. H.; Chalmers, D. K.; Pouton, C. W. Digestion of Phospholipids after Secretion of Bile into the Duodenum Changes the Phase Behavior of Bile Components. Mol. Pharmaceutics 2014, 11 (8), 2825-2834.
39. Roda, A.; Hofmann, A. F.; Mysels, K. J. The influence of bile salt structure on self-association in aqueous solutions. J. Biol. Chem. 1983, 258 (10), 6362-70.
40. Ottaviani, G.; Wendelspiess, S.; Alvarez-Sanchez, R. Importance of critical micellar concentration for the prediction of solubility enhancement in biorelevant media. Mol. Pharmaceutics 2015, 12 (4), 1171-9.
41. Schreier, S.; Malheiros, S. V. P.; de Paula, E. Surface active drugs: self-association and interaction with membranes and surfactants. Physicochemical and biological aspects. Biochim. Biophys. Acta, Biomembr. 2000, 1508 (1-2), 210-234.
42. Mithani, S. D.; Bakatselou, V.; TenHoor, C. N.; Dressman, J. B. Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm. Res. 1996, 13 (1), 163-7.
43. Gautschi, N.; Bergstrom, C. A.; Kuentz, M. Rapid determination of drug solubilization versus supersaturation in natural and digested lipids. Int. J. Pharm. 2016, 513 (1-2), 164-174.
44. Murata, Y.; Sugihara, G.; Fukushima, K.; Tanaka, M.; Matsushita, K. Study of the micelle formation of sodium deoxycholate. Concentration dependence of carbon-13 nuclear magnetic resonance chemical shift. J. Phys. Chem. 1982, 86 (24), 4690-4694.
45. Vogtherr, M.; Marx, A.; Mieden, A. C.; Saal, C. Investigation of solubilising effects of bile salts on an active pharmaceutical ingredient with unusual pH dependent solubility by NMR spectroscopy. Eur. J. Pharm. Biopharm. 2015, 92, 32-41.
46. Vlahcevic, Z. R.; Buhac, I.; Bell, C. C.; Swell, L. Abnormal metabolism of secondary bile acids in patients with cirrhosis. Gut 1970, 11 (5), 420-422.
47. Lapidus, A.; Åkerlund, J.-E.; Einarsson, C. Gallbladder bile composition in patients with Crohn's disease. World J. Gastroenterol 2006, 12 (1), 70-74.
48. Kuno, T.; Hirayama-Kurogi, M.; Ito, S.; Ohtsuki, S. Effect of Intestinal Flora on Protein Expression of Drug-Metabolizing Enzymes and Transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice. Mol. Pharmaceutics 2016, 13 (8), 2691-701.
49. Wuelfing, W. P.; Daublain, P.; Kesisoglou, F.; Templeton, A.; McGregor, C. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species. Mol. Pharmaceutics 2015, 12 (4), 1031-9.
50. Ridlon, J. M.; Kang, D. J.; Hylemon, P. B. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 2006, 47 (2), 241-59.
51. Berr, F.; Kullak-Ublick, G. A.; Paumgartner, G.; Munzing, W.; Hylemon, P. B. 7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology 1996, 111 (6), 1611-20.
52. Coreta-Gomes, F. M.; Vaz, W. L.; Wasielewski, E.; Geraldes, C. F.; Moreno, M. J. Quantification of Cholesterol Solubilized in Dietary Micelles: Dependence on Human Bile Salt Variability and the Presence of Dietary Food Ingredients. Langmuir 2016, 32 (18), 4564-74.